Related Experiment Video
Updated: Sep 12, 2025
09:43
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
8.2K
Plot twist: TET2 clones save the brain.
Maria A Telpoukhovskaia1, Jennifer J Trowbridge1
1The Jackson Laboratory, Bar Harbor, ME, USA.
Cell Stem Cell
|August 8, 2025
Summary
Clonal hematopoiesis (CH) may protect against Alzheimer's disease (AD). This study reveals TET2-mutant CH, not DNMT3A-mutant CH, offers protection by impacting dementia pathology and cognition.
Area of Science:
- Neuroscience
- Hematology
- Genetics
Background:
- Clonal hematopoiesis (CH) is linked to reduced Alzheimer's disease (AD) risk.
- Mechanisms underlying CH's protective effects against AD remain largely unknown.
- Understanding these mechanisms is crucial for developing new AD therapies.
Purpose of the Study:
- To investigate the specific mechanisms by which TET2-mutant and DNMT3A-mutant clonal hematopoiesis influence Alzheimer's disease pathology and cognitive function.
- To differentiate the impact of different CH-associated mutations on neurodegeneration.
Main Methods:
- Analysis of individuals with TET2 or DNMT3A mutations and varying degrees of clonal hematopoiesis.
- Assessment of cognitive function and AD biomarkers.
- Examination of neuropathological hallmarks in relevant models.
Main Results:
- TET2-mutant CH was associated with distinct impacts on dementia pathology and cognitive performance.
- DNMT3A-mutant CH did not show the same protective association.
- Specific molecular pathways influenced by TET2 mutations were identified.
Conclusions:
- TET2-mutant clonal hematopoiesis confers protection against Alzheimer's disease progression.
- The findings highlight the differential roles of TET2 and DNMT3A mutations in CH-related neuroprotection.
- This research opens avenues for targeted therapeutic strategies for AD.
